Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Candesartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candesartan SCHEMBL29508236 | 1.00 | AGTR1 (0.73) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL29682351 | 1.00 | AGTR1 (0.73) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL19357208 | 1.00 | AGTR1 (0.73) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL16237819 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL7292788 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL27825805 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL28786878 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL5507160 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL27825863 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| Candesartan SCHEMBL27825804 | 0.99 | AGTR1 (0.72) | AGTR1ABCB11EGFRERBB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29844 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747238-A1 | PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS | Sanofi (FR) | 2026-05-27 | — | — | EP | claimed |
| US-20260124180-A1 | METHOD OF TREATING AFFECTIVE DISORDERS AND PERSONALITY DISORDERS | HB BIOTECH, INC. (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4724060-A1 | FORMULATIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HB Biotech, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594278-B2 | Method for treatment of muscular dystrophy | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2026-04-07 | — | — | US | claimed |
| EP-4215194-B1 | COMBINATION THERAPY OF AT1 R BLOCKER AND CCR2 INHIBITOR FOR THE TREATMENT, AMELIORATION OR PREVENTION OF A KIDNEY DISEASE | DIMERIX BIOSCIENCE PTY LTD (AU) | 2026-03-25 | — | — | EP | claimed |
| US-12582601-B2 | Orodispersible powder composition | BIOPHARMA SYNERGIES, S.L. (ES) | 2026-03-24 | — | — | US | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | claimed |
| WO-1995001176-A1 | USE OF AN ANGIOTENSIN II ANTAGONIST AS AN OCULAR HYPOTENSIVE AGENT | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-12 | — | — | WO | claimed |
| EP-0631780-A1 | Use of an angiotensin II antagonist as an ocular hypotensive agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| EP-0628313-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-14 | — | — | EP | claimed |
| EP-0622077-A1 | Angiotensin II antagonists as a prophylactic or therapeutic drug for renal diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-02 | — | — | EP | claimed |
| EP-0612523-A1 | Vascular hypertrophy suppressor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0612524-A1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | claimed |